42. The memorandum states that "[tjhere will be a meeting to select the next ten
compounds for testing against human H13V by Brent Korba of Georgetown".
(Exh. 2018).
43. Neither Dr. Painter nor Dr. Furman is on the distribution list found at the bottom
of the memorandum.
44. Ms. Kondy of BW testified that she reported to Dr. Biron and that part of her
duties was to collect samples from BW chemists and forward them to Dr. Korba
for anti-HBV testing. (Exh. 2052 at T$ 3, 4).
45. According to Ms. Kondy, she sent samples from George Painter to Dr. Korba for
anti-HBV testing and recorded the samples in her notebook on 31 October 1990.
(Exh. 2052 at ý 6).
46. Furman has submitted evidence that is said to be a notebook page from Ms.
Kondy's notebook. (Exh. 2011).
47. On the page, under the notation "from G. Painter", is a list consisting of BCH-] 89
and five other Liotta samples.
48. Of the four Liotta samples said to exhibit anti-HIV activity (Exh. 2045), only
BCH- 189 appears on the list.
Dr. Korba's test results:
49. According to Furman, Dr. Korba tested BCH- 189 in an in vitro assay (test) that
utilizes a human cell line transfected with HBV DNA (Paper 88 at 10).
50. Furman has submitted evidence that appears to be a report dated
17
Page: Previous 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Next
Last modified: November 3, 2007